home > epc > summer 2019 > the changing face of clinical data
European Pharmaceutical Contractor

The Changing Face of Clinical Data

Data collection and analysis have always been central to the development of new clinical interventions such as drug treatments, diagnostics, and medical devices. While clinical data have always been collected and analysed, in recent years emerging methods and technologies for collection, analysing and utilising data, as well as the sheer quantity of data collected have been changing, driven by innovation and an evolving drug development landscape.

Clinical data can take many forms, but are essentially any information collected about an individual over the course of their admission and treatment in a medical setting. These data can range from their medical record information (such as age and medical history), the clinical interventions they undergo (such as blood tests, drugs prescribed, and surgical procedures), and the resulting outcomes following an intervention. These measures form the basis of any clinical trial that seeks to establish the efficacy or safety of a novel drug treatment, medical device, or diagnostic.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Aiden Flynn is the Founder of Exploristics and has more than 20 years’ experience in drug discovery and clinical development. After seven years as a lecturer at University College London, UK, Aiden spent 10 years at GlaxoSmithKline as a Director of statistical support for biomarker studies across R&D. In recent years, he has worked closely with the FDA and EMEA to develop tools and guidelines that support the use of biomarkers in clinical studies. Since founding Exploristics in 2009, Aiden has attracted over 50% of the world’s top pharma companies as clients, as well as many biotechnology, device, and diagnostic companies.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Senior Vice President Dr. David Daniel Honored in PharmaVOICE 100

Philadelphia, PA – August 1, 2019: Signant Health (formerly CRF Health and Bracket) today announces that its Senior Vice President, Dr. David Daniel, has been selected by PharmaVOICE as one of the top 100 most inspiring people within the life sciences sector. Dr. Daniel was selected from a large cross section of established professionals in the life sciences industry for his passion to continually improve the way in which science, technology and service interact. This honor swiftly follows another recent mark of distinction for Dr. Daniel, having been co-awarded the 2019 ISCDD Scientific Leadership Award.
More info >>

White Papers

Autoinjector testing made safe efficient and flexible


The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement